Article

Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH(3) receptor affinities

Institut für Pharmazeutische Chemie, Goethe-Universität Frankfurt am Main, Frankfurt, Hesse, Germany
Bioorganic & Medicinal Chemistry (Impact Factor: 2.95). 06/2003; 11(10):2163-74. DOI: 10.1016/S0968-0896(03)00120-2
Source: PubMed

ABSTRACT In this study, a novel series of imidazole-containing compounds with dual properties, that is, inhibitory potency at the enzyme histamine N(tau)-methyltransferase (HMT) and antagonist potency at histamine H(3) receptors was designed and synthesized. Pharmacologically, these new hybrid drugs were evaluated in functional assays for their inhibitory potencies at rat kidney HMT and for their antagonist activities on synaptosomes of rat cerebral cortex. For selected compounds, binding affinities at recombinant human histamine H(3) receptors were determined. The first compounds (1-10) of the series proved to be H(3) receptor ligands of high potency at rat synaptosomes or of high binding affinity at human H(3) receptors, respectively, but of only moderate activity as inhibitors of rat kidney HMT. In contrast, aminoquinoline- or tetrahydroacridine-containing derivatives 11-17 also displayed HMT inhibitory potency in the nanomolar concentration range. Preliminary data from molecular modeling investigations showed that the imidazole derivative 15 and the HMT inhibitor quinacrine possess identical binding areas. The most interesting compound (14) is simultaneously a highly potent H(3) receptor ligand (K(i)=4.1nM) and a highly potent HMT inhibitor (IC(50)=24nM), which makes this derivative a valuable pharmacological tool for further development.

Download full-text

Full-text

Available from: Holger Stark, Jan 06, 2014
1 Follower
 · 
102 Views
  • Source
    • "Multitarget ligands displaying dual H 3 R antagonist/histamine N-methyltransferase (HMT) inhibiting properties are able to greatly enhance histaminergic neurotransmission by simultaneously combining histamine-releasing properties (via H 3 autoreceptor blockade), release of other neurotransmitters by complex receptor cross talk, and reduced catabolic rate for inactivation (via HMT inhibition) [19] [20] [21] [22] [23]. This novel approach of hybrid compounds targeting both H 3 R and HMT could contribute to the elevation of intersynaptic histamine levels in the CNS and might have therapeutic applications in psychiatric and neurodegenerative diseases [10,19–23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In an effort to design dual acting compounds enhancing histaminergic neurotransmission in the central nervous system, a novel class of 35 non-imidazole histamine H-3 receptor (H3R) antagonists that simultaneously possess strong inhibitory potency on catabolic histamine N-methyltransferase (HMT), have been examined by 3D-QSAR study. For improved understanding, the crucial chemical functionalities for combined H3R/HMT activities 3D-QSAR pharmacophore models (H3R: R-2 (0.98), Q(2)(0.94), RMSE (0.171); and HMT: R-2 (0.80), Q(2) (0.60), RMSE (0.159) were developed. Pharmacophore for H3R antagonistic activity mainly differs from pharmacophore for HMT inhibiting activity in presence of specific lipophilic/steric components of the H3R pharmacophore, H-bond accepting components of the H3R pharmacophore, H-bond donating components of the HMT pharmacophore, and longer optimal distance between H-bond donor and steric hot spots in the H3R pharmacophore than in the HMT pharmacophore. Formed 3D-QSAR models were applied for design of novel piperidino-aminoquinoline hybrids as multitarget H3R/HMT ligands with potential impact in therapy of sleep-wake disorders and cognitive impairment. Designed compounds with 3D-QSAR predicted pKi (H3R) > 9.6 and (pKi (H3R) + pIC(50)(HMT)) > 16.8 were selected for further profiling. Virtual screening of ZINC database is performed against the most promising H3R/HMT ligand and top ranked compounds are tested by both 3D-QSAR models.
    Journal of the Taiwan Institute of Chemical Engineers 01/2015; 46. DOI:10.1016/j.jtice.2014.09.017 · 3.00 Impact Factor
  • Source
    • "Multitarget ligands displaying dual H 3 R antagonist/histamine N-methyltransferase (HMT) inhibiting properties are able to greatly enhance histaminergic neurotransmission by simultaneously combining histamine-releasing properties (via H 3 autoreceptor blockade), release of other neurotransmitters by complex receptor cross talk, and reduced catabolic rate for inactivation (via HMT inhibition) [19] [20] [21] [22] [23]. This novel approach of hybrid compounds targeting both H 3 R and HMT could contribute to the elevation of intersynaptic histamine levels in the CNS and might have therapeutic applications in psychiatric and neurodegenerative diseases [10,19–23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Imidazoline receptor ligands are a numerous family of biologically active compounds known to produce central hypotensive effect by interaction with both α2-adrenoreceptors (α2-AR) and imidazoline receptors (IRs). Recent hypotheses connect those ligands with several neurological disorders. Therefore some IRs ligands are examined as novel centrally acting antihypertensives and drug candidates for treatment of various neurological diseases. Effective Blood-Brain Barrier (BBB) permeability (Pe) of 18 IRs/α-ARs ligands and 22 Central Nervous System (CNS) drugs was experimentally determined using Parallel Artificial Membrane Permeability Assay (PAMPA) and studied by the Quantitative-Structure-Permeability Relationship (QSPR) methodology. The dominant molecules/cations species of compounds have been calculated at pH = 7.4. The analyzed ligands were optimized using Density Functional Theory (B3LYP/6-31G(d,p)) included in ChemBio3D Ultra 13.0 program and molecule descriptors for optimized compounds were calculated using ChemBio3D Ultra 13.0, Dragon 6.0 and ADMET predictor 6.5 software. Effective permeability of compounds was used as dependent variable (Y), while calculated molecular parametres were used as independent variables (X) in the QSPR study. SIMCA P+ 12.0 was used for Partial Least Square (PLS) analysis, while the stepwise Multiple Linear Regression (MLR) and Artificial Neural Networks (ANN) modeling were performed using STASTICA Neural Networks 4.0. Predictive potential of the formed models was confirmed by Leave-One-Out Cross- and external-validation and the most reliable models were selected. The descriptors that are important for model building are identified as well as their influence on BBB permeability. Results of the QSPR studies could be used as time and cost efficient screening tools for evaluation of BBB permeation of novel α-adrenergic/imidazoline receptor ligands, as promising drug candidates for treatment of hypertension or neurological diseases.
    European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 12/2014; 68. DOI:10.1016/j.ejps.2014.12.014 · 3.01 Impact Factor
  • Source
    • "iodoproxyfan binding assay to human histamine H 3 receptors stably expressed in CHO cells (Apelt et al. 2002; Grassmann et al. 2003); b HMT assay on isolated enzyme from rat kidneys (Apelt et al. 2002; Grassmann et al. 2003); c AChE assay on whole blood samples from humans (Worek et al. 1999), CI confidence interval; d BuChE assay on heparinized human blood (Worek et al. 1999), CI confidence interval; e n.d. not determined containing compounds we started with compound 1 for initial screening, which showed inhibitory potencies on cholinesterases comparable to those of the reference compound tacrine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine. H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease. Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine. Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine. Preliminary structure-activity relationships could already be drawn from the small number of compounds. The compounds acting as hybrid drugs simultaneously on four different targets to enhance cognitive functions via different pathways are promising lead structures for a new approach in the treatment of Alzheimer's disease.
    Pharmazie 04/2006; 61(3):179-82. · 1.00 Impact Factor
Show more